ATS: Tezepelumab Reduces Asthma Exacerbations Across Asthma Phenotypes

MONDAY, May 18, 2026 (HealthDay News) -- For patients with severe, uncontrolled asthma, tezepelumab is associated with substantial reductions in asthma exacerbations across asthma phenotypes and underrepresented populations, according to a study published online May 18 in the American Journal of Respiratory and Critical Care Medicine to coincide with the American Thoracic Society 2026 International Conference, held from May 15 to 20 in Orlando, Florida.Njira Lugogo, M.D., from the University of Michigan in Ann Arbor, and colleagues examined the effectiveness and safety of tezepelumab in a diverse, real-world cohort of 286 U.S. patients (adults and adolescents) with severe, uncontrolled asthma that included different asthma phenotypes and underrepresented populations. Participants received 210 mg tezepelumab subcutaneously every four weeks for 52 weeks.Of the patients enrolled, 42 percent had a blood eosinophil count ≥300 cells/µL, 58 percent had positive allergy status, 22 percent were Black/African American, 7 percent were adolescents, 20 percent had comorbid chronic obstructive pulmonary disease, and 29 percent were smokers. The researchers found that the annualized asthma exacerbation rate decreased by 70 percent overall between the baseline and treatment periods and by 54 to 77 percent across asthma phenotypes and underrepresented populations. Clinically meaningful improvements from baseline were seen in 74, 63, and 80 percent of patients in the Asthma Control Questionnaire-6, Asthma Impairment and Risk Questionnaire, and St. George's Respiratory Questionnaire scores at week 52 overall, with robust results seen across asthma phenotypes and underrepresented populations (ranges: 64 to 86, 51 to 75, and 63 to 91 percent, respectively). During the treatment period after tezepelumab initiation, 9.8 percent of patients reported a serious adverse event."The study results were really reassuring in terms of both safety and efficacy," Lugogo said in a statement.The study was sponsored by AstraZeneca, the manufacturer of tezepelumab.Abstract/Full TextMore Information.Sign up for our weekly HealthDay newsletter

ATS: Tezepelumab Reduces Asthma Exacerbations Across Asthma Phenotypes

Related Stories

Gap Found Between Awareness of Breast Cancer Risk and Risk-Reducing Behavior

2018 to 2025 Saw Sharp Rise in Postpartum GLP-1 Receptor Agonist Use

ASTRO: <30 Percent With ER+ Early-Stage Breast Cancer Remain on Endocrine Therapy at Five Years

Polypharmacy of Prescription Medications Increased for U.S. Older Adults